Clover Health Investments Corp (CLOV) concluded trading on Thursday at a closing price of $4.49, with 6.59 million shares of worth about $29.58 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 41.19% during that period and on February 20, 2025 the price saw a loss of about -1.32%. Currently the company’s common shares owned by public are about 394.44M shares, out of which, 376.52M shares are available for trading.
Stock saw a price change of 0.45% in past 5 days and over the past one month there was a price change of 5.90%. Year-to-date (YTD), CLOV shares are showing a performance of 42.54% which increased to 352.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.61 but also hit the highest price of $4.87 during that period. The average intraday trading volume for Clover Health Investments Corp shares is 5.33 million. The stock is currently trading -0.12% below its 20-day simple moving average (SMA20), while that difference is up 16.29% for SMA50 and it goes to 62.05% higher than SMA200.
Clover Health Investments Corp (NASDAQ: CLOV) currently have 394.44M outstanding shares and institutions hold larger chunk of about 18.56% of that.
The stock has a current market capitalization of $2.25B and its 3Y-monthly beta is at 2.00. It has posted earnings per share of -$0.19 in the same period. It has a debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLOV, volatility over the week remained 4.64% while standing at 5.67% over the month.
Stock’s fiscal year EPS is expected to rise by 73.20% while it is estimated to decrease by -16.51% in next year. EPS is likely to grow at an annualized rate of 46.63% for next 5-years, compared to annual growth of -585.84% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on December 17, 2024 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by UBS stated Clover Health Investments Corp (CLOV) stock as a Neutral in their note to investors on October 07, 2024, suggesting a price target of $4 for the stock. On February 02, 2022, Cowen Upgrade their recommendations, while on February 02, 2022, Canaccord Genuity Initiated their ratings for the stock with a price target of $6. Stock get a Mkt perform rating from SVB Leerink on January 19, 2022.
